Insider Selling: Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Sells 450 Shares of Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now directly owns 821 shares of the company’s stock, valued at approximately $402,519.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Intuitive Surgical Trading Down 1.6 %

Shares of NASDAQ:ISRG opened at $483.32 on Wednesday. The company has a market cap of $171.43 billion, a PE ratio of 87.24, a price-to-earnings-growth ratio of 5.41 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $496.18. The stock has a 50 day moving average of $465.50 and a 200 day moving average of $423.39.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.18 earnings per share. Equities research analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ISRG. Stifel Nicolaus lifted their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research note on Friday, July 19th. Barclays raised their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. Citigroup increased their target price on Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Piper Sandler lifted their price target on shares of Intuitive Surgical from $490.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Finally, Robert W. Baird lifted their price objective on Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $446.45.

Hedge Funds Weigh In On Intuitive Surgical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. University of Texas Texas AM Investment Management Co. bought a new position in Intuitive Surgical during the second quarter valued at $416,000. Sanctuary Advisors LLC bought a new position in shares of Intuitive Surgical in the 2nd quarter valued at about $22,957,000. Clear Rock Advisors LLC purchased a new position in Intuitive Surgical in the second quarter worth about $216,000. Sycomore Asset Management increased its stake in Intuitive Surgical by 28.6% during the second quarter. Sycomore Asset Management now owns 9,120 shares of the medical equipment provider’s stock worth $4,036,000 after acquiring an additional 2,027 shares during the last quarter. Finally, Clearbridge Investments LLC raised its position in Intuitive Surgical by 1.6% during the second quarter. Clearbridge Investments LLC now owns 1,981,297 shares of the medical equipment provider’s stock valued at $881,380,000 after purchasing an additional 30,449 shares during the period. 83.64% of the stock is owned by institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.